Definium Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

Definium Therapeutics Inc. (DFTX) — NEW YORK, August 06, 2026--Definium Therapeutics, Inc. ("Definium" or the "Company") (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today reported financial results for the quarter ended June 30, 2026, and recent highlights.

Source: Business Wire — read the full announcement there.

Browse more sector announcements in our press release archive.